420 with CNW – Cannabis Inhalers Could Be the Next Asthma and Cancer Pain Medication

April 15, 2019 03:20:08

Whole smoking is the most common administration method for medical cannabis, not all patients are willing or able to use this method. For example, those who have respiratory challenges like asthma are unable to smoke cannabis because it may aggravate their condition. Terminally ill patients may also find it hard to smoke marijuana as part of their treatment. For such patients, two Israeli companies have teamed up to develop cannabis inhalers through which they can take their medication.

The two firms are Panaxia Pharmaceuticals and Rafa Pharmaceuticals. The two companies are working together to bring marijuana inhalers to the market so that patients have one more way to get their medication.

For now, the companies are targeting asthma and the pain suffered by cancer patients. The companies hope to avail an administration mode that will bring quick relief to cancer pain or respiratory distress resulting from asthma symptoms.

This administration mode may easily gain acceptance in the market for several reasons.

First, inhalers aren’t a new mode of administering medication to patients. Asthma sufferers carry them around, so it would not be hard for them to switch to the cannabis version.

Secondly, it is possible to determine what precise dose of cannabis a patient should receive when using inhalers since the patient can be told to inhale a given number of times at stipulated intervals in order to get the right dose of cannabis into the body. Medical practitioners can therefore easily see cannabis as medicine if its dosage can be controlled.

Additionally, inhalation can provide faster therapeutic outcomes when compared to other modes, such as consuming cannabis edibles. This is precisely why asthma sufferers often carry an inhaler so that they can use it and see results faster when an asthma attack occurs.

At the moment, the innovators are conducting clinical trials together with the Israeli Ministry of Health in order to ascertain whether the product is ready to hit the market, or some kinks remain which need to be resolved.

Meanwhile, the companies have decided to start a marketing drive for the inhalers while the clinical trial is ongoing.

The plan is to avail the inhalers on the Israel market later this year. Only patients with a doctor’s prescription will be able to access the product. It is not yet clear when the two companies will start exporting their invention to the rest of the world. Remember, the Israeli parliament passed a law towards the end of last year allowing companies that have been licensed by the state to export medical marijuana.

Youngevity International, Inc. (NASDAQ: YGYI) and Cannabis Strategic Ventures, Inc. (OTC: NUGS) congratulate the two Israeli companies for finding a solution to administering medical cannabis to patients who are unable to use the modes that are currently available on the market.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

Denver, Colorado
303.498.7722 Office